GRACE KIM to Treatment Outcome
This is a "connection" page, showing publications GRACE KIM has written about Treatment Outcome.
Connection Strength
0.183
-
Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease. Arthritis Rheumatol. 2020 02; 72(2):316-325.
Score: 0.052
-
Impact of quantitative radiological features of interstitial lung disease on immunomodulatory treatment response in three autoimmune interstitial lung disease cohorts. Thorax. 2025 07 15; 80(8):540-546.
Score: 0.019
-
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. Am J Respir Crit Care Med. 2024 08 15; 210(4):424-434.
Score: 0.018
-
Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study. Ther Adv Respir Dis. 2024 Jan-Dec; 18:17534666241287307.
Score: 0.017
-
Procedural outcomes associated with use of the AngioVac System for right heart thrombi: A safety report from RAPID registry data. Vasc Med. 2022 06; 27(3):277-282.
Score: 0.015
-
Endovascular Removal of Thrombus and Right Heart Masses Using the AngioVac System: Results of 234 Patients from the Prospective, Multicenter Registry of AngioVac Procedures in Detail (RAPID). J Vasc Interv Radiol. 2021 04; 32(4):549-557.e3.
Score: 0.014
-
Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. Int J Cancer. 2021 04 15; 148(8):1928-1937.
Score: 0.014
-
Inflammation, Active Fibroplasia, and End-stage Fibrosis in 172 Biliary Atresia Remnants Correlate Poorly With Age at Kasai Portoenterostomy, Visceral Heterotaxy, and Outcome. Am J Surg Pathol. 2018 12; 42(12):1625-1635.
Score: 0.012
-
Improved Cough and Cough-Specific Quality?of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. Chest. 2017 Apr; 151(4):813-820.
Score: 0.011
-
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
Score: 0.010